INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Aldeyra Therapeutics and its officers/directors following a significant stock price drop after the FDA's response regarding the company's drug application [1][3]. Company Summary - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) received a Complete Response Letter from the FDA regarding its New Drug Application (NDA) for reproxalap, indicating that the application failed to demonstrate efficacy in treating dry eye disease [3]. - The FDA's letter highlighted that no manufacturing or safety issues were identified, but concerns were raised about the data from the trial, which may have been affected by methodological issues [3]. - Following the FDA's announcement, Aldeyra's stock price plummeted by $3.90, or 73.31%, closing at $1.42 per share on April 3, 2025 [3]. Legal Investigation - Pomerantz LLP is actively seeking claims from investors of Aldeyra, suggesting that there may be grounds for a class action lawsuit due to the alleged securities fraud [1]. - The firm has a long history in corporate and securities class litigation, having recovered multimillion-dollar damages for victims of securities fraud and corporate misconduct [4].